Bavarian Nordic — September 2017
-
Fra Nordea "Tonight Bavarian Nordic announced that the independent Data Monitoring Committee (DMC), based on third interim analysis in the PROSTPECT trial, has recommended that the ph III trial be stopped due to futility (no significant effect). This is quite unexpected; we anticipated the trial would continue to completion. This is of course a clear negative and the stock will take a significant hit tomorrow (likely 30% or more).
-
Godmorgen til alle. Det var ikke så godt med Prostvac, - jeg havde set den hjemme og står selv til en her på ørene her til morgen - en ret stor en af slagsen. Men husk lige ; at selv om man måske mister ret mange penge , er det centrale i denne situation, ikke at handle overilet,men heller ikke at lade stå til i afmagt. Damagecontrol er altså det centrale.Husk ingen døde og ingen sårede og livet er dejligt.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind